

A prospective, single-center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against COVID-19

1 Jayanthi Shastri^{1*}, Sachee Agrawal¹, Nirjhar Chatterjee¹, Harsha Gupta¹

2 ¹Kasturba Hospital for Infectious Diseases, Mumbai, India.

3 * Correspondence:

4 Dr. Jayanthi S. Shastri

5 Head, Molecular Diagnostic Reference Laboratory

6 Kasturba Hospital for Infectious Diseases,

7 Mumbai-400034, Maharashtra, India.

8 E-mail: jsshastri@gmail.com

9 **Number of words:** 3457

10 **Number of Tables:** 5

11 **Number of Figures:** 1

12 **Abstract**

13 **Background:** Accurate rapid antibody detection kits requiring minimum infrastructure are beneficial
14 in detecting post-vaccination antibodies in large populations. ChAdOx1-nCOV (COVISHIELD™)
15 and BBV-152 (Covaxin™) vaccines are primarily used in India.

16 **Methods:** In this single-centre prospective study, performance of Meril ABFind was investigated by
17 comparing with Abbott SARS-CoV-2 IgG II Quant (Abbott Quant), GenScript cPass SARS-CoV-2
18 neutralization antibody detection kit (GenScript cPass), and COVID Kawach MERILISA
19 (MERILISA) in 62 vaccinated health care workers (HCW) and 40 pre-pandemic samples.

20 **Results:** In the vaccinated subjects, Meril ABFind kit displayed high sensitivity of 93.3% (CI,
21 89.83%-96.77%), 94.92% (CI, 91.88%-97.96%), and 90.3% (CI, 86.20%-94.4%) in comparison to
22 Abbott Quant, MERILISA, and GenScript cPass respectively. The results of the Meril ABFind in the
23 COVISHIELD-vaccinated group were excellent with 100% sensitivity in comparison to the other
24 three kits. In the Covaxin-vaccinated group, Meril ABFind displayed sensitivity ranging from 80% to
25 88.9%. In control samples, there were no false positives detected by Meril ABFind, while Abbott
26 Quant, MERILISA, and GenScript cPass reported 2.5%, 10.0%, and 12.5% false positives,
27 respectively. In the pre-pandemic controls, specificity of Meril ABFind was 100%, Abbott Quant
28 97.5%, MERILISA 90%, and GenScript cPass 87.5%.

29 **Conclusion:** The Meril ABFind kit demonstrated satisfactory performance when compared with the
30 three commercially available kits and was the only kit without false positives in the pre-pandemic
31 samples. This makes it a viable option for rapid diagnosis of post vaccination antibodies.

32 **Keywords:** SARS-CoV-2, COVID-19, adaptive immunity, humoral immunity, neutralizing
33 antibodies, antibodies, rapid test.

34 1 Introduction

35 SARS-CoV-2 which belongs to Betacoronavirus genus and Coronaviridae family is the causative
36 agent for COVID-19. The spike protein (S-glycoprotein) present on the surface of the virus has a
37 receptor binding domain (RBD) which binds to the angiotensin-converting enzyme 2 (ACE2) present
38 on the cell surfaces and mediates the entry of this virus inside the host cell (1). Within the first three
39 weeks of getting infected with the virus, the patients develop antibodies against the RBD of the viral
40 spike protein (2). Early development of antibodies is important for survival and control of infection
41 in the patients. These neutralizing antibodies provide protection from future infection by interfering
42 with the interaction between the virus's spike RBD and host's ACE2.

43 India has primarily used ChAdOx1-nCOV (COVISHIELD™) and BBV-152 (Covaxin™) vaccines
44 with health care workers (HCW) being the first group to get vaccinated. Serological tests can detect
45 the humoral immune response following past infection and vaccination, and they can be useful for
46 serological studies. Serology has also been used to make clinical decision on therapeutic
47 interventions (3). While accurate laboratory based serological assays are available in India, a large
48 rural population mandates reliable serological assays to detect humoral immunity following
49 vaccination and post infection which can be performed without expensive laboratory equipment and
50 cumbersome techniques. To address this unmet need, several companies are working on the
51 development of reliable antibody testing kits with adequate sensitivity and specificity (4). Different
52 diagnostic kits are available to identify individuals with immune response after the vaccine
53 administration. Testing a huge number of vaccinated individuals with a diagnostic assay which
54 requires complicated instruments and infrastructure would be cumbersome and would not be
55 economical. In the given situation, a rapid test would be advantageous owing to speed of
56 performance, quick results and minor requirements of equipments and infrastructure.

57 The Meril ABFind kit (Meril Diagnostics Pvt. Ltd., India) can detect circulating SARS-CoV-2
58 neutralizing antibodies that block the interaction between the RBD of the viral spike glycoprotein and
59 the ACE2 cell surface receptor in serum, plasma and whole blood. This study was designed to
60 investigate the clinical performance of this rapid antibody testing kit by evaluating its diagnostic
61 sensitivity and specificity for the qualitative detection of neutralizing antibodies in defined and
62 characterized specimens. For evaluating the performance of this kit, the results obtained were
63 compared with the results obtained using three other commercially available kits viz. Abbott SARS-
64 CoV-2 IgG II Quant (Abbott Diagnostic, USA), GenScript cPass SARS-CoV-2 neutralization
65 antibody detection Kit (GenScript, USA), and COVID Kawach MERILISA (Meril Diagnostic, Pvt.
66 Ltd., India).

67 2 Materials & Methods

68 2.1 Study Participants

69 A total of 62 participants of which 32 had been vaccinated with COVISHIELD and 30 with Covaxin,
70 were recruited for this study in the months of June, July and August 2021. All recruited participants
71 were health care workers working in the city of Mumbai, India. The inclusion criteria for the study
72 were: healthcare workers in the age range of 18 to 60 years, fully vaccinated, i.e., two weeks after the
73 second dose of COVISHIELD or Covaxin and less than 12 weeks after the second dose of
74 COVISHIELD or Covaxin. Any individual who reported symptoms suggestive of COVID-19 were to
75 be excluded, however none of the participants showed any such symptoms. The study was approved
76 by the Institutional Review Board of Kasturba Hospital of Infectious Diseases, Mumbai, India; IRB
77 number 05/2021. Written informed consent was obtained from all study participants. All collection,
78 processing of samples and archiving of results were performed under approval from the Institutional
79 Review Board.

80 The baseline demographics and the medical history of the participants were collected for analysis and
81 evaluation.

82 2.2 Sample collection:

83 One 5 ml vial of blood was collected by venipuncture from the cubital vein in serum separator tubes.
84 Separated plasma was used for testing in all four tests. 40 stored pre-pandemic samples were used as
85 a known negative control. These samples were collected in 2018 from patients with an acute febrile
86 illness. Plasma was separated and stored at -80 °C in our laboratory (Molecular Laboratory, Kasturba
87 Hospital for Infectious Diseases, Mumbai, India).

88 2.3 Serological Tests

89 All the samples were tested first using Abbott SARS-CoV-2 IgG II Quant (Abbott Quant). Then the
90 samples were tested using the Meril ABFind kit and the two commercially available kits, COVID
91 Kawach MERILISA (MERILISA) and GenScript cPass SARS-CoV-2 neutralization antibody
92 detection kit (GenScript cPass).

93 The Abbott Quant kit results were beneficial in comparing anti-RBG IgG in the COVISHIELD- and
94 Covaxin-vaccinated subjects in a quantitative manner. Meril ABFind kit is a qualitative membrane-
95 based immunoassay for the detection of SARS-CoV-2 neutralizing antibody in whole blood, serum
96 or plasma. This detection kit utilizes a colloidal gold labeled SARS-CoV-2 recombinant Receptor
97 Binding Domain (rRBD) which binds with the SARS-CoV-2 neutralizing antibody of IgG class if
98 present in the sample to give a colored band. A control band must be present for the test to be
99 considered valid. A control band and a test band was considered positive, a control band without a
100 test band was considered negative and absence of the control band was considered invalid
101 irrespective of the test band. The test specimen was diluted in 1:10 ratio with sample dilution buffer
102 and was added on the membrane strip, the results were read at the end of 20 minutes.

103 The Abbott SARS-CoV-2 IgG II Quant assay is a two-step automated chemi-luminescent
104 microparticle immunoassay (CMIA) intended for the qualitative and quantitative determination of
105 IgG antibodies to the RBD of the spike protein of SARS-CoV-2 in human serum and plasma. The
106 analytical measurement interval was stated as 21 to 40,000 AU/ml, and positivity cut off was
107 ≥ 50 AU/ml (defined by manufacturer) (5).

108 GenScript cPass SARS-CoV-2 neutralization antibody detection kit is a blocking ELISA detection
109 tool which mimics the virus neutralization process. It uses horseradish peroxidase (HRP) conjugated
110 recombinant RBD protein and human angiotensin converting enzyme-2 (ACE-2) receptor protein.
111 The protein interaction between HRP-RBD and ACE-2 can be blocked by neutralizing antibodies
112 against SARS-CoV-2 RBD. Signal inhibition was calculated as follow:

113
$$\text{Percent Signal Inhibition} = (1 - \frac{\text{average optical density value of sample}}{\text{average optical density value}} \\ \text{of negative control}) \times 100\%$$

115 The test results were interpreted as positive when the percent signal inhibition was $\geq 30\%$, which was
116 the cut-off for signal inhibition claimed by the manufacturer (6).

117 Covid Kawach MERILISA is an immune assay based on indirect enzyme linked immunosorbent
118 assay principle for qualitative detection of IgG antibodies against SARS-CoV-2 in the sample. The
119 optical density (OD) of the plate is read at 450 nm. This kit comes with a positive and negative
120 control which works as marker of the kit. P/N ratio of positive control is defined as ratio of OD value
121 of positive control to the average of the ODs of negative control. The test is considered to be valid if
122 P/N ratio of positive control is greater than 1.5.

123 Cut off calculations = Average negative control + 0.2

124 For the test sample, if OD value was greater than the cut-off value and P/N ratio was more than 1.5,
125 sample was considered positive. While, for the test sample, if OD value was less than the cut-off
126 value and P/N ratio was less than 1.5, sample was considered negative (7).

127 **2.4 Managing Test Results**

128 Results of all four tests were given to participants with the understanding that testing was done in the
129 context of a research study. No clinical decisions were made on the basis of this study. Participants
130 were informed that a positive result did not preclude COVID-19 in the future and that a negative
131 result did not necessarily mean lack of protection against COVID-19.

132 **2.5 Statistical analysis**

133 Continuous variables like age were summarized with mean \pm SD, and categorical variables like gender
134 were presented with count (%). Primary analyses, to evaluate diagnostic accuracy of the
135 investigational kit, were reported with % for sensitivity and specificity. 95% confidence interval is
136 specified for sensitivity and specificity. Positive predictive value specifies the proportions of true
137 positive and negative predictive value specifies the proportions of true negative. In the vaccinated
138 groups, true positives are the samples that tested positive using the study kit and the comparator kit
139 and true negatives are the samples that tested negative using the study kit and the comparator kit. If
140 the sample test positive with the gold standard but negative with the investigational kit, it was
141 considered as false negative. If the sample test negative with the gold standard but positive with the
142 investigational kit, it was considered as false positive. For pre-pandemic control samples, all the
143 samples were considered as true negative as the samples were collected in 2018 before the emergence
144 of SARS-CoV-2 and therefore antibodies against SARS-CoV-2 could not be present in these
145 samples. So, in this group, any positives detected were considered as false positive and all negatives
146 reported were considered true negatives. Sensitivity and specificity were calculated using the
147 formulae:

148 Sensitivity: $(\text{True positive}) / (\text{True positive} + \text{False negative})$

149 Specificity: $(\text{True negative}) / (\text{True negative} + \text{False positive})$ (6)

150 3 Results

151 Demographic data of the subjects in the vaccinated group (n=62) are presented in Table 1. The
152 samples were collected at a median 62 (16-84) days after the second dose of vaccination in the
153 cohort of the total vaccinated population. The mean age of this population was 36.5 ± 11.58 years; of
154 which 43.75% were male and 56.25% were female. Among this population, presence of co-
155 morbidities such as hypertension, heart disease, and diabetes were 6.45%, 1.61%, and 4.84%,
156 respectively. Demographic details and co-morbidities for the COVISHIELD- and Covaxin-
157 vaccinated groups are presented separately in Table 1.

158 For further clarity, we performed individual analysis of all four kits for both the vaccinated groups
159 separately (Table 2). Analyses of Meril ABFind kit versus the other three kits as gold standard in the
160 combined vaccinated cohort, COVISHIELD-vaccinated group and Covaxin-vaccinated group are
161 shown in Table 3. In the combined vaccinated population, the Meril ABFind kit displayed 93.3%
162 (CI, 89.83%-96.77%), 94.92% (CI, 91.88%-97.96%), and 90.3% (CI, 86.20%-94.4%) sensitivity in
163 comparison to Abbott Quant, MERILISA, and GenScript cPass, respectively.

164 In the COVISHIELD-vaccinated group, the results obtained with Meril ABFind kit were compared
165 to the results obtained with other three kits considering them as “gold standard”. Samples from all
166 the COVISHIELD recipients were positive by all four tests kits. The sensitivity of Meril ABFind kit
167 in comparison to all the other three kits in this group was 100%. The positive predictive value
168 calculated for Meril ABFind kit versus other three kits was also observed to be 100% In the
169 Covaxin-vaccinated group, Meril ABFind kit displayed 85.7% (CI, 71.79%-99.71%), 88.9% (CI,
170 76.33%-100%), and 80% (CI, 64%-96%) sensitivity in comparison to Abbott Quant, MERILISA,
171 and GenScript cPass, respectively. The specificity of the Meril ABFind kit in comparison to all the
172 three kits was 100%.

173 The 40 pre-pandemic control samples tested with these four different kits showed different positive
174 and negative results (Table 4). In the pre-pandemic controls, the Meril ABFind kit did not produce
175 any false positive results. However, all the other three kits, Abbott Quant, MERILISA, and
176 GenScript cPass did produce false positive results; 1, 4 and 5 false positives each, respectively. In
177 this group, the specificity of Meril ABFind kit, Abbott Quant, MERILISA, and GenScript cPass
178 were reported to be 100%, 97.5%, 90%, and 87.5% respectively.

179 Quantitative antibody responses were significantly higher ($p=0.01$) after COVISHIELD vaccination
180 (2889.36 ± 3572 AU/mL; CI 1651.72 to 4127) versus Covaxin vaccination (1054.13 ± 1360.01
181 AU/mL; CI 582.90 to 1525.35) detected by the Abbott Quant kit (Table 5).

182 4 Discussion

183 Previous studies have shown that neutralizing antibodies are targeted against spike protein,
184 specifically the RBD and N-terminal domain of SARS-CoV-2 (8-10). Of monoclonal antibodies
185 isolated from SARS-CoV-2 infected individuals, almost all those which potently neutralized SARS-
186 CoV-2 *in vitro* were against RBD and a few against N-terminal domain (11).

187 Meril ABFind kit is based on detection of IgG antibodies against RBD in the specimens. This study
188 evaluated the sensitivity and specificity of Meril ABFind kit in detecting COVID-19 antibodies in
189 the samples collected from a diverse population. In this study, we had two groups of samples, one
190 from COVID-19 vaccinated (either with COVISHIELD or Covaxin) group and the other from a pre-
191 pandemic control group. The vaccinated group was further divided into a COVISHIELD-vaccinated
192 group and a Covaxin-vaccinated group. The two vaccinated groups were comparable in terms of age
193 and presence of pre-existing medical conditions (diabetes, hypertension, heart disease). The timing
194 of sample collection from the second dose was also comparable in both the vaccinated groups.

195 The manufacturer claimed sensitivity and specificity of Abbott Quant were 99.35% and 99.6% (12),
196 Covid Kawach MERILISA were approximately 93% and 100% (7) and GenScript cPass were
197 93.80% and 99.40%, respectively (13). Previous studies have also reported the sensitivity and
198 specificity of the comparator kits. In one study, Abbott Quant kit demonstrated 96% sensitivity and
199 99.3% specificity in comparison to GenScript cPass (6). The Abbott Quant kit was also used in
200 investigating the anti-spike IgG responses in health care workers following one or two doses of
201 Pfizer-BioNTech or Oxford-Astrazenca vaccines (14). The GenScript cPass SARS-CoV-2
202 neutralization antibody detection kit is the first commercially available kit to detect neutralizing
203 antibodies against SARS-CoV-2 RBD. One of the initial studies with this kit reported the sensitivity
204 and specificity of this kit in the range of 77-100% and 95-100%, respectively, in comparison to
205 plaque-reduction neutralization test and pseudo typed lentiviral neutralization assay (15). For our
206 study, we have compared the performance of Meril ABFind kit with the other three commercially
207 available kits and have not performed comparative analysis amongst the comparator kits. However,
208 from the number of positive and negative cases detected, it can be inferred that the performance of all
209 the kits used in this study were not identical.

210 The performance of the Meril ABFind kit was evaluated by comparing with the performance of the
211 comparator kits viz. Abbott Quant, MERILISA, and GenScript cPass in both the groups. In the
212 vaccinated population, the Meril ABFind kit displayed sensitivity of over 90% with all three
213 comparators; 93.3% (CI, 89.83%-96.77%) with Abbott Quant, 94.92% (CI, 91.88%-97.96%) with
214 MERILISA, and 90.3% (CI, 86.20%-94.4%) with GenScript cPass.

215 In the COVISHIELD-vaccinated group, in comparison to the other three kits the Meril ABFind kit
216 displayed 100% sensitivity. As all the four kits have reported positive results and there were no
217 negatives reported by any of them, calculating specificity of the kits was not valid for this group.

218 In the Covaxin-vaccinated group, the Meril ABFind kit had a sensitivity of 85.7% (CI, 71.79%-
219 99.71%) with Abbott Quant, 88.9% (CI, 76.33%-100%) with MERILISA, and 80% (CI, 64%-96%)
220 with GenScript cPass. The specificity was 100% against all three comparator tests.

221 A study in India comparing anti-Spike antibody responses following COVISHIELD and Covaxin
222 found that seropositivity and geometric mean titers were higher following COVISHIELD
223 vaccination compared to Covaxin vaccination (16). In our study, a significantly higher ($p=0.01$) level
224 of anti-RBD IgG antibodies were detected in the COVISHIELD-vaccinated group versus the
225 Covaxin-vaccinated group by the Abbott Quant kit. This may explain why Meril ABFind had a

226 better sensitivity in the COVISHIELD group compared to the Covaxin group. Additionally, Meril
227 ABFind does not detect antibodies against non-RBD epitopes. Covaxin is a whole virus inactivated
228 vaccine and generates antibody responses against Spike and non-Spike antigens, while Meril
229 ABFind only detects antibodies against the RBD. However, our study was not designed to compare
230 the seropositivity between COVISHIELD- and Covaxin-vaccinated individuals. Based on our study,
231 we cannot comment on the immunogenicity or efficacy of COVISHIELD compared with Covaxin.

232 The control samples were collected before the pandemic, and in this group the results of all four kits
233 differed. It was deemed impossible for these samples to contain antibodies against specific SARS-
234 CoV-2 antigens as these samples were collected in 2018. Any positives in these samples would
235 necessarily be false positives due to cross reactivity with antibodies against other endemic
236 coronaviruses or other non-coronavirus pathogens. These samples were collected from patients with
237 an acute febrile illness which included dengue and leptospirosis but may have also included other
238 infectious diseases which may have resulted in cross reactivity and false positives.

239 In the pre-pandemic control samples, all positive results by Abbott Quant, MERILISA, and
240 GenScript cPass were classified as false positive results as it was not possible for these samples to
241 contain antibodies against SARS-CoV-2. The Meril ABFind kit did not produce a single false
242 positive in the pre-pandemic controls, and therefore in this cohort, Meril ABFind kit was 100%
243 specific, which was better than Abbott Quant IgG II, MERILISA, and GenScript cPass (Figure 1).

244 Interestingly, Abbott Quant, MERILISA, and GenScript cPass detected 2.5%, 10%, and 12.5% false
245 positives, respectively. As all three of these kits (Abbott Quant, MERILISA, and GenScript cPass
246 kits) produced false-positive results in the pre-pandemic samples, it is possible that they produced
247 some false positives in the samples from the Covaxin-vaccinated subjects as well. It is possible that
248 Meril ABFind displayed a higher sensitivity in the Covaxin group while the comparator kits (Abbott
249 Quant, MERILISA, and GenScript cPass) displayed specificity lower than reported in literature. It
250 would be prudent to assess these assays in a large cohort of pre-pandemic samples from India to
251 ensure absence of cross-reactivity against non-SARS-CoV-2 coronaviruses or other pathogens.

252 Currently, many diagnostic kits which were developed to detect antibodies against SARS-CoV-2 in
253 specimens collected from infected and vaccinated individuals against COVID-19 are commercially
254 available. The rapid lateral flow serological assays were the first commercially available serological
255 assays, but their poor sensitivity and specificity made them unsuitable for use (11). Since then
256 numerous laboratory-based assays, for example CLIA & ELISA have been introduced in India with
257 reported high sensitivity and specificity. However, there is a lack of laboratory infrastructure,
258 technical expertise in rural India for such assays. Serological assays have demonstrated great value
259 in serological studies to understand the percentage of the population that has COVID-19 antibodies.
260 Such studies will continue to be relevant in the future. Serology has also been used to guide clinical
261 decision making. In the UK, NHS guidelines recommend offering a combination of casirivimab and
262 imdevimab to people aged 12 and over in hospital with COVID-19 who have no detectable SARS-
263 CoV-2 antibodies (seronegative) (3). This treatment works best when administered early in disease
264 course and accurate point of care serological tests may offer value in this setting. While serology is
265 not currently used to guide decisions on vaccination, it is possible that in the future decisions on the
266 need for additional doses of COVID-19 vaccines or boosters will be based on serology. Therefore,
267 an accurate point of care serological test may offer value in future serological studies, clinical
268 decision making and vaccination programs. A rapid and accurate serological assay that can detect
269 post vaccination COVID-19 neutralizing antibodies would be especially useful in areas where
270 laboratory facilities are not available.

271 In this study, the Meril ABFind kit showed excellent sensitivity and specificity in the

272 COVISHIELD- and Covaxin-vaccinated groups. Notably, Meril ABFind kit was the only assay in
273 this study that had a zero false positivity rate and 100% specificity in the pre-pandemic samples,
274 while all three comparator kits had some false positives. This suggests the conventional thought
275 process that rapid point of care tests are necessarily less accurate or specific than laboratory based
276 assays may not always hold true, at least as concerns SARS-CoV-2 serological tests.

277 Our study also highlights the need to investigate laboratory based assays for cross reactivity in the
278 Indian population. If we had not used pre-pandemic samples as a control, we would have missed the
279 possibility that Abbott Quant, MERILISA, and GenScript cPass had a false positivity rate as high as
280 2.5%, 10% and 12.5%. While it is important to have sensitive assays that can correctly detect all
281 individuals who have an adaptive humoral response to SARS-CoV-2, it is equally important to
282 ensure that an assay is specific and doesn't incorrectly label those who do not have antibodies as
283 being sero-positive, particularly for neutralizing antibodies against SARS-COV-2. False positive
284 results in serological studies may result in over-estimating the population that has antibodies from
285 infection and vaccination, and this may have important implications on policy decisions. A false
286 positive result may disqualify an individual from a therapeutic like a monoclonal antibody cocktail
287 when it is dependant on serological status.

288 Our study shows that point of care serological tests can be a suitable alternative to laboratory based
289 assays. Meril ABFind kit has an excellent sensitivity and specificity in comparison to commercially
290 available laboratory assays and holds promise in accurate identification of SARS-CoV-2 anti-RBD
291 neutralizing antibodies. In our study, Meril ABFind kit was the only assay that didn't produce false
292 positives. The results of the control pre-pandemic samples show that the Meril ABFind kit had the
293 highest specificity in pre-pandemic control samples. However, larger studies with larger sample size
294 are warranted to provide conclusive evidence of comparative performance of all the kits used in this
295 study.

296 **5 Conflict of Interest**

297 The authors declare that the research was conducted in the absence of any commercial or financial
298 relationships that could be construed as a potential conflict of interest.

299 **6 Author Contributions**

300 JS conceptualized the study. SA, NC and HG collected and compiled data. JS, SA, NC and HG
301 drafted the manuscript, prepared tables and figures. All authors contributed to data interpretation,
302 writing, critically reviewing, revising, and approving the final manuscript for submission.

303 **7 Funding**

304 This work was supported by the Municipal Corporation of Greater Mumbai's funding for Kasturba
305 Hospital's COVID-19 diagnostic laboratory. GenScript cPass SARS-CoV-2 neutralization antibody
306 detection kits, COVID Kawach MERILISA kits and Meril ABFind kits were provided by Meril
307 Diagnostic Pvt Limited.

308 **8 Acknowledgments**

309 The authors acknowledge and thank the Municipal Corporation of Greater Mumbai for their support
310 through the study. We thank Meril Diagnostic Pvt. Limited for providing test kits to conduct the
311 study. We thank the health workers who participated in this study.

312 **9 Data Availability Statement**

313 The original contributions presented in the study are included in the article. Further inquiries can be
314 directed to the corresponding author.

315 10 References

- 316 1. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, *et al.* Author Correction:
317 Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. *Nat Commun*
318 (2021) 12:2996. doi: 10.1038/s41467-020-18319-6.
- 319 2. Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, *et al.* Neutralizing
320 antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
321 *Nat Commun* (2021) 12:2670. doi: 10.1038/s41467-021-22958-8.
- 322 3. National Institute of Health and Care Excellence. (2021).
323 <https://www.nice.org.uk/guidance/ng191/chapter/Recommendations> [Accessed November 11, 2021].
- 324 4. Petherick A. Developing antibody tests for SARS-CoV-2. *Lancet* (2020) 395:1101-2. doi:
325 10.1016/S0140-6736(20)30788-1 .
- 326 5. English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the Abbott
327 SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC
328 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global
329 Harmonization of COVID-19 Antibody Methods. *J clin microbiol* (2021) 59:e0028821. doi:
330 10.1128/JCM.00288-21.
- 331 6. Jung K, Shin S, Nam M, Hong YJ, Roh EY, Park KU, *et al.* Performance evaluation of three
332 automated quantitative immunoassays and their correlation with a surrogate virus neutralization test
333 in coronavirus disease 19 patients and pre-pandemic controls. *J clin lab anal* (2021) 35:e23921. doi:
334 10.1002/jcla.23921.
- 335 7. Meril Life Sciences Pvt. Ltd. (2021). [https://www.merillife.com/medical-](https://www.merillife.com/medical-devices/diagnostics/covid-19/immunology/covid-kavach-merilisa)
336 [devices/diagnostics/covid-19/immunology/covid-kavach-merilisa](https://www.merillife.com/medical-devices/diagnostics/covid-19/immunology/covid-kavach-merilisa) [Accessed November 11, 2021].
- 337 8. Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, *et al.* A SARS-CoV-
338 2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. *Cell* (2020)
339 182:744-53.e4. doi: 10.1016/j.cell.2020.06.011
- 340 9. Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
341 *Antib Ther* (2020) 3:109-14. doi: 10.1093/abt/tbaa009.
- 342 10. Huang Y, Sun H, Yu H, Li S, Zheng Q, Xia N. Neutralizing antibodies against SARS-CoV-2:
343 current understanding, challenge and perspective. *Antib Ther* (2020) 3:285-99. doi:
344 10.1093/abt/tbaa028.
- 345 11. Meschi S, Colavita F, Bordi L, Matusali G, Lapa D, Amendola A, *et al.* Performance
346 evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect
347 immunofluorescence and virus microneutralization test. *J clin virol* (2020) 129:104539. doi:
348 10.1016/j.jcv.2020.104539.
- 349 12. Abbott. (2021). [https://abbott.mediaroom.com/2020-12-15-Abbott-Receives-CE-Mark-for-its-](https://abbott.mediaroom.com/2020-12-15-Abbott-Receives-CE-Mark-for-its-COVID-19-IgG-Quantitative-Antibody-Blood-Test)
350 [COVID-19-IgG-Quantitative-Antibody-Blood-Test](https://abbott.mediaroom.com/2020-12-15-Abbott-Receives-CE-Mark-for-its-COVID-19-IgG-Quantitative-Antibody-Blood-Test) [Accessed on November 13, 2021].
- 351 13. GenScript. (2021). <https://www.genscript.com/covid-19-detection-ce.html> [Accessed on
352 November 13, 2021].
- 353 14. Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, *et al.* Quantitative SARS-CoV-2
354 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection
355 status. *Clin microbiol infect* (2021) 27:1516.e7-.e14. doi: 10.1016/j.cmi.2021.05.041.

- 356 15. Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza E, Manguiat K, *et al.* Evaluation of a
357 Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory
358 Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-
359 Linked Immunosorbent Assay. *Open forum infect dis* (2021) 8:ofab220. doi: 10.1093/ofid/ofab220.
- 360 16. Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, *et al.* Antibody
361 response after first and second-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152
362 (Covaxin™®) among health care workers in India: The final results of cross-sectional coronavirus
363 vaccine-induced antibody titre (COVAT) study. *Vaccine* (2021) 39:6492-509. doi:
364 10.1016/j.vaccine.2021.09.055

365

366 **Table legends:**

367 **Table 1:** Demographic details of the participants

368 **Table 2:** Performance of different antibody detecting kits in COVISHIELD-vaccinated group and
369 Covaxin-vaccinated group

370 **Table 3:** Analysis of Meril ABFind kit versus the other three kits as gold standard in the combined
371 vaccinated cohort, COVISHIELD-vaccinated group and Covaxin-vaccinated group

372 **Table 4:** Performance of different antibody detecting kits in pre-pandemic control samples

373 **Table 5:** Quantitative determination of SARS-CoV -2 antibodies in COVISHIELD -vaccinated and
374 Covaxin-vaccinated group by Abbott Quant

375

376

377

378 **Figure Legends:**

379 **Figure 1:** Specificity of the four kits in the pre-pandemic control group

380

381

382

383

384

385

386

387

388

389

390

391

392

Table 1: Demographic details of the participants

Characteristics	Combined vaccinated cohort	COVISHIELD -vaccinated group	Covaxin-vaccinated group
Age	36.65±11.58	36.56±12.20	36.73±11.09
Gender			
Male	21(43.75)	14 (43.75)	7 (23.33)
Female	41(56.25)	18 (56.25)	23 (76.67)
Time span between 2nd dose of vaccine and blood collection (Days)			
Average (Mean±SD)	58.45±19.61	62.33±21.62	55.46±17.63
Median (Min,Max)	62(16,84)	70 (16, 84)	58 (22, 83)
Comorbidity, n(%)			
Hypertension	4(6.45)	2(6.25)	2(6.67)
heart disease	1(1.61)	1(3.13)	0 (0)
Diabetes	3(4.84)	1(3.13)	2(6.67)

393

394

395

396 **Table 2: Performance of different antibody detecting kits in COVISHIELD -vaccinated group**
397 **and Covaxin-vaccinated group**

	COVISHIELD-vaccinated group				Covaxin-vaccinated group			
Results	Meril ABFind (n=32)	Abbott IgG II (n=32)	MERILIS A (n=32)	GenScript (n=32)	Meril ABFind (n=30)	Abbott IgG II (AU/mL) (n=30)	MERILIS A (n=30)	GenScript (n=30)
Positive	32	32	32	32	24	28	27	30
Negative	0	0	0	0	6	2	3	0

398 (Abbott IgG II, Abbott SARS-CoV-2 IgG II Quant; GenScript, GenScript cPass SARS-CoV-2
399 neutralization antibody detection Kit; MERILISA, Covid Kawach MERILISA)

400

401 **Table 3: Analysis of Meril ABFind kit versus the other three kits as gold standard in the**
 402 **combined vaccinated cohort, COVISHIELD-vaccinated group and Covaxin-vaccinated group**

Parameters	Combined vaccinated cohort			COVISHIELD-vaccinated group			Covaxin-vaccinated group		
	Meril ABFind vs Abbott IgG II	Meril ABFind vs MERILISA	Meril ABFind vs GenScript	Meril ABFind vs Abbott IgG II	Meril ABFind vs MERILISA	Meril ABFind vs GenScript	Meril ABFind vs Abbott IgG II	Meril ABFind vs MERILISA	Meril ABFind vs GenScript
Sensitivity	93.3%	94.92%	90.3%	100%	100%	100%	85.7%	88.9%	80%
Specificity	100%	100%	NA	NA	NA	NA	100%	100%	NA
Positive predictive value	100%	100%	100%	100%	100%	100%	100%	100%	NA
Negative predictive value	33.3%	50%	NA	NA	NA	NA	100%	100%	100%
Confidence Interval for Sensitivity	89.83% to 96.77%	91.88% to 97.96%	86.20% to 94.40%	NA	NA	NA	71.71 to 99.71	76.33 to 100.00	64.00 to 96.00

403 (Abbott IgG II, Abbott SARS-CoV-2 IgG II Quant; GenScript, GenScript cPass SARS-CoV-2
 404 neutralization antibody detection Kit; MERILISA, Covid Kawach MERILISA)

405

406 **Table 4: Performance of different antibody detecting kits in pre-pandemic control samples**

Results, n(%)	Meril ABFind (N=40)	Abbott IgG II (N=40)	MERILISA (N=40)	GenScript (N=40)
Specificity	40(100%)	39(97.5%)	36(90%)	35(87.5%)
False positive	0	1(2.5%)	4(10%)	5(12.5%)

407 (Abbott IgG II, Abbott SARS-CoV-2 IgG II Quant; GenScript, GenScript cPass SARS-CoV-2
408 neutralization antibody detection Kit; MERILISA, Covid Kawach MERILISA)


409

410

411

412 **Table 5: Quantitative determination of SARS-CoV-2 antibodies in COVISHIELD-vaccinated**
413 **and Covaxin-vaccinated group by Abbott Quant**

	Abbott Quant (AU/mL)		p-value
Vaccines	COVISHIELD-vaccinated (n=32)	Covaxin-vaccinated (n=30)	
Mean ± SD	2889.36 ± 3571.99	1054.13 ± 1360.01	0.010
95% CI	1651.72 to 4126.99	582.90 to 1525.35	
Min, Max	83.4, 13611.7	11.9, 5632.1	



414

415

Figure 1: Specificity of the four kits in the pre-pandemic control group